Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.
(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Researchers identified several antibodies to the nucleocapsid protein from a convalescent COVID-19 patient. Tests found some can inhibit complement hyperactivation and could potentially lead to new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results